MedPath

Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation

Not Applicable
Conditions
Atrial Fibrillation
Interventions
Registration Number
NCT01991951
Lead Sponsor
Korea University Anam Hospital
Brief Summary

We hypothesized that in patients with low CHADS-VASc score (2 or \< 2), there is no difference in thromboembolic or bleeding events between patients with short term warfarin therapy (2 weeks after catheter ablation) and conventional therapy (3 weeks before and 8 weeks after procedure).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
520
Inclusion Criteria
  • Patients with paroxysmal atrial fibrillation who underwent radiofrequency catheter ablation
  • Patients with CHADS-VASc score 2 or less than 2
Exclusion Criteria
  • Patients who do not consent to the study
  • Permanent or persistent atrial fibrillation
  • Patients who have underwent prior catheter ablation for atrial fibrillation
  • CHADS-VASc score more than 2
  • History of stroke
  • LVEF <40%
  • Significant liver or kidney dysfunction
  • History of major bleeding during warfarin therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Short term warfarin groupwarfarintaking warfarin for only 2 weeks after catheter ablation of atrial fibrillation
Conventional therapy armwarfarinconventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF
Primary Outcome Measures
NameTimeMethod
Incidence of thromboembolic and bleeding events during 2 months2 months after the procedure
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath